Company / R&D per Share
ArriVent BioPharma, Inc. R&D per Share History
FY2023-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$2.51
FY2024
5-year range
$2.51 / $30.31
FY2023-FY2024
Trend
-91.7%
vs FY2023
Sector context
#84 of 208
Health Care
What the data says
At $2.51, ArriVent BioPharma, Inc.'s r&d per share ranks #84 of 208 in the Health Care sector.
Based on SEC 10-K filings.
2.51 in FY2024.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#84 of 208 in Health CareTop 40% of 208This company $2.51 Sector average $28.82
▼
-91.3% below sector average
Key checks
Key Insights
- In FY2024, r&d per share decreased 91.7% year-over-year.
- Ranks #84 out of 208 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 5.74 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $2.51 | -91.7% |
| FY2023 | $30.31 | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026